Status:
ACTIVE_NOT_RECRUITING
Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma
Lead Sponsor:
National Eye Institute (NEI)
Conditions:
Retinal Hemangioblastoma
Von Hippel-Lindau Disease
Eligibility:
All Genders
7-120 years
Brief Summary
Background: Retinal hemangioblastoma (RH) is a tumor. It grows from the retina in the eye. It can threaten a person s vision. Trans-scleral cryotherapy is used to destroy the tumors and minimize the ...
Detailed Description
Study Description: This study is a retrospective review of medical records in the NIH eye clinic. To our knowledge, there has been no report in the current era dedicated to a description of trans-scle...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Participants were enrolled in NEI and non-NEI natural history protocols, but in all cases, cryotherapy was administered as a standard care measure (not as an investigative treatment).
- Patients were identified by searching the NIH eye clinic EMR for all of those manifesting one or more retinal hemangioblastomas (with or without associated von Hippel-Lindau disease) treated with cryotherapy.
- EXCLUSION CRITERIA:
- None
Exclusion
Key Trial Info
Start Date :
July 2 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2026
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04458935
Start Date
July 2 2020
End Date
June 30 2026
Last Update
August 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Eye Institute (NEI)
Bethesda, Maryland, United States, 20892